FR2470599A1
(fr)
*
|
1979-12-07 |
1981-06-12 |
Panoz Donald |
Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
|
DE3314003A1
(de)
*
|
1983-04-18 |
1984-10-18 |
Boehringer Ingelheim KG, 6507 Ingelheim |
Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
|
US5185159A
(en)
*
|
1983-07-20 |
1993-02-09 |
Sanofi |
Pharmaceutical composition based on valproic acid and a process for preparing it
|
US5002776A
(en)
*
|
1983-12-22 |
1991-03-26 |
Elan Corporation, Plc |
Controlled absorption diltiazem formulations
|
IE56999B1
(en)
*
|
1983-12-22 |
1992-03-11 |
Elan Corp Plc |
Pharmaceutical formulation
|
US4917899A
(en)
*
|
1983-12-22 |
1990-04-17 |
Elan Corporation Plc |
Controlled absorption diltiazem formulation
|
SE457505B
(sv)
*
|
1984-01-10 |
1989-01-09 |
Lejus Medical Ab |
Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
|
DE3431861A1
(de)
*
|
1984-08-30 |
1986-03-13 |
Troponwerke GmbH & Co KG, 5000 Köln |
Pellet-zubereitung
|
JPH0653658B2
(ja)
*
|
1984-12-17 |
1994-07-20 |
中外製薬株式会社 |
安定な錠剤の製造法
|
EP0187703B1
(de)
*
|
1985-01-11 |
1992-08-05 |
Teijin Limited |
Präparate mit verzögerter Freisetzung
|
FR2576213B1
(fr)
*
|
1985-01-21 |
1989-02-24 |
Cortial |
Nouveau procede d'obtention de formes pharmaceutiques a liberation prolongee
|
US4912146A
(en)
*
|
1985-01-30 |
1990-03-27 |
Warner-Lambert Company |
Coated dosage forms
|
US4913906B1
(en)
*
|
1985-02-28 |
2000-06-06 |
Yissum Res Dev Co |
Controlled release dosage form of valproic acid
|
LU85943A1
(fr)
*
|
1985-06-12 |
1987-01-13 |
Galephar |
Comprimes pharmaceutiques permettant l'administration aisee de pellets, leur preparation et leur utilisation
|
CH666405A5
(de)
*
|
1985-06-24 |
1988-07-29 |
Ciba Geigy Ag |
Feste, haltbare darreichungsformen mit elastischem filmueberzug.
|
EP0212746B1
(de)
*
|
1985-08-16 |
1991-04-10 |
The Procter & Gamble Company |
Partikel mit konstanter Wirkstofffreisetzung
|
DE3678644D1
(de)
*
|
1985-08-16 |
1991-05-16 |
Procter & Gamble |
Wirkstoffpartikel mit sowohl kontinuierlicher als auch schneller freisetzung.
|
EP0212745B1
(de)
*
|
1985-08-16 |
1991-04-10 |
The Procter & Gamble Company |
Partikel mit konstanter Wirkstofffreisetzung
|
JPS6248618A
(ja)
*
|
1985-08-27 |
1987-03-03 |
Zeria Shinyaku Kogyo Kk |
徐放性製剤およびその製造法
|
GB8521350D0
(en)
*
|
1985-08-28 |
1985-10-02 |
Euro Celtique Sa |
Analgesic composition
|
GB8521494D0
(en)
*
|
1985-08-29 |
1985-10-02 |
Zyma Sa |
Controlled release tablet
|
LU86077A1
(fr)
*
|
1985-09-18 |
1987-04-02 |
Pharlyse Sa |
Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques
|
EP0225085A1
(de)
*
|
1985-11-13 |
1987-06-10 |
ELAN CORPORATION, Plc |
Arzneiformulierung mit gesteuerter Absorption
|
US4983400A
(en)
*
|
1986-06-16 |
1991-01-08 |
Merck & Co., Inc. |
Controlled release combination of carbidopa/levodopa
|
IE58401B1
(en)
*
|
1986-06-20 |
1993-09-08 |
Elan Corp Plc |
Controlled absorption pharmaceutical composition
|
CH669523A5
(de)
*
|
1986-06-25 |
1989-03-31 |
Mepha Ag |
|
SE460947B
(sv)
*
|
1986-08-26 |
1989-12-11 |
Lejus Medical Ab |
En multiple-unit-dos komposition av l-dopa
|
SE460945B
(sv)
*
|
1987-01-15 |
1989-12-11 |
Lejus Medical Ab |
En multipel-unit-dos komposition av furosemid
|
CA1324083C
(en)
*
|
1987-03-09 |
1993-11-09 |
Tetsu Miyoshi |
Pharmaceutical preparations containing non-steroidal anti-inflammatory agents
|
GB8707421D0
(en)
*
|
1987-03-27 |
1987-04-29 |
Wellcome Found |
Pharmaceutical formulations
|
US4837211A
(en)
*
|
1987-04-06 |
1989-06-06 |
Carolina Medical Products, Inc. |
Spironolactone composition
|
US5277916A
(en)
*
|
1988-02-01 |
1994-01-11 |
F. H. Faulding & Co., Ltd. |
Tetracycline dosage form
|
GB8805695D0
(en)
*
|
1988-03-10 |
1988-04-07 |
Nycomed As |
Enteric coated spheroidal granules
|
FI101344B
(fi)
†
|
1988-03-31 |
1998-06-15 |
Tanabe Seiyaku Co |
Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseut tisesti aktiivista ainetta
|
US4925675A
(en)
*
|
1988-08-19 |
1990-05-15 |
Himedics, Inc. |
Erythromycin microencapsulated granules
|
US4925674A
(en)
*
|
1988-08-25 |
1990-05-15 |
Himedics, Inc. |
Amoxicillin microencapsulated granules
|
CA1338596C
(en)
*
|
1988-09-27 |
1996-09-17 |
Hiroyoshi Koyama |
Granules having core and their production
|
JPH082781B2
(ja)
*
|
1988-10-18 |
1996-01-17 |
嘉明 川島 |
中空顆粒状医薬及びその製法
|
US5178868A
(en)
*
|
1988-10-26 |
1993-01-12 |
Kabi Pharmacia Aktiebolaq |
Dosage form
|
US5026559A
(en)
*
|
1989-04-03 |
1991-06-25 |
Kinaform Technology, Inc. |
Sustained-release pharmaceutical preparation
|
PT93637A
(pt)
*
|
1989-04-20 |
1990-11-20 |
Procter & Gamble |
Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
|
DE3920082A1
(de)
*
|
1989-06-20 |
1991-03-07 |
Roehm Gmbh |
Filmbildendes waessriges ueberzugsmittel fuer feste arzneimittel, verfahren zu seiner herstellung und verwendung
|
US5047258A
(en)
*
|
1989-07-14 |
1991-09-10 |
Sterling Drug Inc. |
Aqueous spray-coating process
|
DK0415688T3
(da)
*
|
1989-08-30 |
1999-08-23 |
Aeci Ltd |
Fremgangsmåde til fremstilling af et doseringssystem samt fremgangsmåde til behandling af en genstand eller et locus
|
US5198228A
(en)
*
|
1989-09-14 |
1993-03-30 |
Hoechst-Roussel Pharmaceuticals Inc. |
Direct dry compressible acetaminophen tablet
|
US5130140A
(en)
*
|
1989-09-14 |
1992-07-14 |
Hoeschst-Roussel Pharmaceuticals Inc. |
Method of making direct dry compressible acetaminophen composition
|
US5037658A
(en)
*
|
1989-09-14 |
1991-08-06 |
Hoechst-Roussel Pharmaceuticals, Inc. |
Direct dry compressible acetaminophen composition
|
DK0418565T3
(da)
*
|
1989-09-21 |
1995-01-23 |
American Cyanamid Co |
Pulserende system til afgivelse af minocyclin en gang dagligt
|
EP0418596A3
(en)
*
|
1989-09-21 |
1991-10-23 |
American Cyanamid Company |
Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
|
IL96311A
(en)
†
|
1989-12-01 |
1995-05-26 |
Abbott Lab |
Medications with delayed release
|
US5175003A
(en)
*
|
1990-04-06 |
1992-12-29 |
Biosytes Usa, Inc. |
Dual mechanism controlled release system for drug dosage forms
|
US5075114A
(en)
*
|
1990-05-23 |
1991-12-24 |
Mcneil-Ppc, Inc. |
Taste masking and sustained release coatings for pharmaceuticals
|
US5460825A
(en)
*
|
1990-05-23 |
1995-10-24 |
Mcneil-Ppc, Inc. |
Taste mask coatings for preparing chewable pharmaceutical tablets
|
GEP19971086B
(en)
*
|
1991-02-22 |
1997-12-02 |
Tillotts Pharma Ag |
Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
|
GB9104854D0
(en)
*
|
1991-03-07 |
1991-04-17 |
Reckitt & Colmann Prod Ltd |
Sustained release compositions
|
US5326570A
(en)
*
|
1991-07-23 |
1994-07-05 |
Pharmavene, Inc. |
Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
|
US5262173A
(en)
*
|
1992-03-02 |
1993-11-16 |
American Cyanamid Company |
Pulsatile once-a-day delivery systems for minocycline
|
AU683044B2
(en)
*
|
1992-12-23 |
1997-10-30 |
Saitec S.R.L. |
Process for preparing controlled release pharmaceutical forms and the forms thus obtained
|
DE4310012A1
(de)
*
|
1993-03-27 |
1994-09-29 |
Roehm Gmbh |
Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
|
SE9301057L
(sv)
*
|
1993-03-30 |
1994-10-01 |
Pharmacia Ab |
Beredning med kontrollerad frisättning
|
SE9301220D0
(sv)
*
|
1993-04-14 |
1993-04-14 |
Kabi Pharmacia Ab |
Manufacturing matrices
|
AU680019B2
(en)
*
|
1993-08-30 |
1997-07-17 |
Warner-Lambert Company Llc |
Tablet coating based on a melt-spun mixture of a saccharide and apolymer
|
US5472714A
(en)
*
|
1993-09-08 |
1995-12-05 |
Ciba-Geigy Corporation |
Double-layered oxcarbazepine tablets
|
ES2145065T3
(es)
*
|
1993-10-27 |
2000-07-01 |
Daiichi Seiyaku Co |
Preparacion granular.
|
RO114740B1
(ro)
*
|
1994-05-06 |
1999-07-30 |
Pfizer |
Compozitie cu eliberare controlata, procedeu de obtinere a acesteia si metoda de tratament
|
DE4423078B4
(de)
*
|
1994-07-01 |
2005-01-13 |
Awd.Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung
|
SE9402431D0
(sv)
*
|
1994-07-08 |
1994-07-08 |
Astra Ab |
New tablet formulation
|
DE69522921T2
(de)
*
|
1994-07-08 |
2002-04-11 |
Astrazeneca Ab |
Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i)
|
SE9500422D0
(sv)
*
|
1995-02-06 |
1995-02-06 |
Astra Ab |
New oral pharmaceutical dosage forms
|
SE512835C2
(sv)
*
|
1996-01-08 |
2000-05-22 |
Astrazeneca Ab |
Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
SE9600071D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral formulation of two active ingredients I
|
SE9600072D0
(sv)
*
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral formulation of two active ingredients II
|
US5773031A
(en)
*
|
1996-02-27 |
1998-06-30 |
L. Perrigo Company |
Acetaminophen sustained-release formulation
|
FR2754177B1
(fr)
*
|
1996-10-07 |
1999-08-06 |
Sanofi Sa |
Microspheres pharmaceutiques d'acide valproique pour administration orale
|
CA2275604A1
(en)
*
|
1997-01-03 |
1998-07-09 |
Kenneth Iain Cumming |
Sustained release cisapride mini-tablet formulation
|
US6140475A
(en)
*
|
1997-04-11 |
2000-10-31 |
Altus Biologics Inc. |
Controlled dissolution crosslinked protein crystals
|
PL337799A1
(en)
*
|
1997-07-01 |
2000-09-11 |
Pfizer Prod Inc |
Sertralin dosage forms of retarded release
|
KR100446366B1
(ko)
|
1997-07-01 |
2004-09-01 |
화이자 인코포레이티드 |
서트랄린 염 및 서트랄린의 서방성 투여형
|
US6274591B1
(en)
*
|
1997-11-03 |
2001-08-14 |
Joseph F. Foss |
Use of methylnaltrexone and related compounds
|
US20030158220A1
(en)
*
|
1997-11-03 |
2003-08-21 |
Foss Joseph F. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
|
US6559158B1
(en)
|
1997-11-03 |
2003-05-06 |
Ur Labs, Inc. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
|
IT1296980B1
(it)
|
1997-12-17 |
1999-08-03 |
Istituto Pirri S R L |
Capsula doppia come forma farmaceutica per la somministrazione di principi attivi in terapie multiple
|
US6541606B2
(en)
|
1997-12-31 |
2003-04-01 |
Altus Biologics Inc. |
Stabilized protein crystals formulations containing them and methods of making them
|
DE19820529A1
(de)
|
1998-05-08 |
1999-11-11 |
Lohmann Therapie Syst Lts |
Wirkstoff enthaltende orale und mucosale Zubereitung mit steuerbarer Wirkstofffreisetzung und ihre Verwendung
|
NZ511442A
(en)
*
|
1998-11-02 |
2003-02-28 |
Elan Corp Plc |
Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
|
SE0102036D0
(sv)
*
|
2001-06-08 |
2001-06-08 |
Axon Biochemicals Bv |
Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
|
CA2449175A1
(en)
*
|
2001-06-05 |
2002-12-12 |
University Of Chicago |
Use of methylnaltrexone to treat immune suppression
|
MXPA04003540A
(es)
*
|
2001-10-15 |
2004-07-22 |
R Hm Gmbh & Co Kg |
Utilizacion de un copolimero para producir una forma galenica que contiene un peptido o proteina como agente activo.
|
US7670612B2
(en)
|
2002-04-10 |
2010-03-02 |
Innercap Technologies, Inc. |
Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
|
AU2003270778B2
(en)
|
2002-09-20 |
2009-10-08 |
Alpharma Pharmaceuticals, Llc |
Sequestering subunit and related compositions and methods
|
AU2003272601B2
(en)
*
|
2002-09-20 |
2009-05-07 |
Alpharma Pharmaceuticals, Llc |
Sustained-release opioid formulations and methods of use
|
MXPA05010819A
(es)
*
|
2003-04-08 |
2006-03-30 |
Progenics Pharm Inc |
Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
|
US20040266806A1
(en)
|
2003-04-08 |
2004-12-30 |
Sanghvi Suketu P. |
Pharmaceutical formulation
|
CA2521420A1
(en)
*
|
2003-04-08 |
2004-10-28 |
Progenics Pharmaceuticals, Inc. |
Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
EP1691786A1
(de)
|
2003-12-04 |
2006-08-23 |
Pfizer Products Inc. |
Multiteilchenförmige zusammensetzungen mit verbesserter stabilität
|
JP2007513145A
(ja)
|
2003-12-04 |
2007-05-24 |
ファイザー・プロダクツ・インク |
医薬用多微粒子の製造方法
|
WO2005053652A1
(en)
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
|
JP2007516259A
(ja)
*
|
2003-12-09 |
2007-06-21 |
メッドクリスタルフォームズ、エルエルシー |
活性剤との混合相共結晶の調製方法
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
DE602004022205D1
(de)
|
2004-09-09 |
2009-09-03 |
Psicofarma S A De C V |
Pharmazeutische zusammensetzung für die verzögerte freisetzung von hydralazin und ihre verwendung als unterstützung zur krebstherapie
|
WO2006046256A1
(en)
*
|
2004-10-27 |
2006-05-04 |
Alembic Limited |
Extended release formulation of pramipexole dihydrochloride
|
US8058291B2
(en)
*
|
2005-04-06 |
2011-11-15 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for the treatment of CNS-related conditions
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
SG157415A1
(en)
|
2004-11-23 |
2009-12-29 |
Adamas Pharmaceuticals Inc |
Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
|
EP1845968A2
(de)
|
2004-11-24 |
2007-10-24 |
Neuromolecular Pharmaceuticals, Inc |
Zusammensetzung mit einem nmda-rezeptor-antagonisten und levodopa und ihre verwendung zur behandlung von neurologischen erkrankungen
|
BRPI0606587A2
(pt)
*
|
2005-01-20 |
2009-07-07 |
Progenics Pharmaceuticais Inc |
uso de metilnaltrexona e compostos correlatos para tratar disfunção gastrintestinal pós-operatória
|
ITBO20050123A1
(it)
*
|
2005-03-07 |
2005-06-06 |
Alfa Wassermann Spa |
Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
MX2007010833A
(es)
*
|
2005-03-07 |
2009-02-17 |
Univ Chicago |
Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
|
AR057035A1
(es)
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
AR057325A1
(es)
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
US20080194611A1
(en)
*
|
2005-06-03 |
2008-08-14 |
Alverdy John C |
Modulation of Cell Barrier Dysfunction
|
WO2007008305A1
(en)
*
|
2005-07-08 |
2007-01-18 |
Cherng-Ju Kim |
Asymmetrically coated tablet
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US9561188B2
(en)
|
2006-04-03 |
2017-02-07 |
Intellipharmaceutics Corporation |
Controlled release delivery device comprising an organosol coat
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US20070270443A1
(en)
*
|
2006-05-19 |
2007-11-22 |
Gregory Went |
Methods and compositions for the treatment of viral infections
|
MX2008016372A
(es)
|
2006-06-19 |
2009-05-28 |
Alpharma Inc |
Composiciones farmaceuticas.
|
US7713549B2
(en)
*
|
2006-06-30 |
2010-05-11 |
Board Of Trustees Of The University Of Arkansas |
Extended release perforated tablet
|
EP2051696A2
(de)
*
|
2006-08-18 |
2009-04-29 |
Morton Grove Pharmaceuticals, Inc. |
Stabile flüssige levetiracetam-zusammensetzungen und verfahren
|
KR20090094336A
(ko)
|
2006-11-27 |
2009-09-04 |
하. 룬트벡 아크티에 셀스카브 |
헤테로아릴 아미드 유도체
|
EP3064503A1
(de)
|
2007-03-29 |
2016-09-07 |
Progenics Pharmaceuticals, Inc. |
Antagonisten der peripheren opioidrezeptoren und ihre verwendung
|
DK2565195T3
(en)
|
2007-03-29 |
2015-06-29 |
Wyeth Llc |
PERIPHERAL OPIOID RECEPTOR AND ANTAGONISTS AND USES THEREOF
|
WO2008121352A2
(en)
|
2007-03-29 |
2008-10-09 |
Progenics Pharmaceuticals, Inc. |
Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof
|
WO2009042778A1
(en)
*
|
2007-09-25 |
2009-04-02 |
Nirmal Mulye |
Controlled release pharmaceutical compositions
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
CN101959892B
(zh)
|
2008-02-06 |
2014-01-08 |
普罗热尼奇制药公司 |
(r),(r)-2,2’-二-甲基纳曲酮的制备和用途
|
US8685995B2
(en)
|
2008-03-21 |
2014-04-01 |
The University Of Chicago |
Treatment with opioid antagonists and mTOR inhibitors
|
WO2010002576A1
(en)
|
2008-07-01 |
2010-01-07 |
University Of Chicago |
Particles containing an opioid receptor antagonist and methods of use
|
CA2676881C
(en)
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
CN103932988A
(zh)
|
2009-04-24 |
2014-07-23 |
伊休蒂卡有限公司 |
吲哚美辛的新剂型
|
CN102781259A
(zh)
|
2009-09-30 |
2012-11-14 |
加利福尼亚大学董事会 |
辅因子及个体使用方法
|
CA2994873A1
(en)
|
2009-12-02 |
2011-06-09 |
Adamas Pharmaceuticals, Inc. |
Amantadine compositions and methods of use
|
JP6158801B2
(ja)
|
2011-07-15 |
2017-07-05 |
ニューサート サイエンシーズ, インコーポレイテッド |
代謝経路を変調させるための組成物および方法
|
ES2641437T3
(es)
*
|
2011-09-16 |
2017-11-10 |
Purdue Pharma Lp |
Formulaciones farmacéuticas resistentes a la manipulación indebida
|
US9198454B2
(en)
|
2012-03-08 |
2015-12-01 |
Nusirt Sciences, Inc. |
Compositions, methods, and kits for regulating energy metabolism
|
KR20150082623A
(ko)
|
2012-11-13 |
2015-07-15 |
뉴서트 사이언시스, 인크. |
에너지 대사를 증가시키기 위한 조성물 및 방법
|
US20150359771A1
(en)
|
2013-01-15 |
2015-12-17 |
Nusirt Sciences, Inc. |
Treating pulmonary conditions
|
KR20150130455A
(ko)
|
2013-03-15 |
2015-11-23 |
뉴서트 사이언시스, 인크. |
지질 수준을 감소시키는 류신 및 니코틴산
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
CN106456997B
(zh)
|
2014-02-27 |
2018-12-28 |
纽斯尔特科学公司 |
用于减少或预防肝性脂肪变性的组合物和方法
|
US9526734B2
(en)
|
2014-06-09 |
2016-12-27 |
Iceutica Pty Ltd. |
Formulation of meloxicam
|
US10058542B1
(en)
|
2014-09-12 |
2018-08-28 |
Thioredoxin Systems Ab |
Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
|
WO2016061531A1
(en)
|
2014-10-17 |
2016-04-21 |
Salix Pharmaceuticals, Inc. |
Use of methylnaltrexone to attenuate tumor progression
|
CA2936748C
(en)
|
2014-10-31 |
2017-08-08 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
WO2018200885A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocentria, Inc. |
Magnesium compositions and methods of use
|
CN111372578A
(zh)
|
2017-08-24 |
2020-07-03 |
阿达玛斯药物有限责任公司 |
金刚烷胺组合物、其制备和使用方法
|
WO2020067887A1
(en)
|
2018-09-24 |
2020-04-02 |
Erasmus University Medical Center Rotterdam |
Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
CN111166729A
(zh)
*
|
2020-03-19 |
2020-05-19 |
珠海赛隆药业股份有限公司 |
一种口服的替加环素肠溶微球及其制备方法
|